Trial Profile
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Therapeutic Use
- 10 Apr 2024 According to an AIM ImmunoTech media release, company Announced Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
- 02 Apr 2024 According to an AIM ImmunoTech media release, Protocol-planned interim results expected in Q2 2024.
- 08 Nov 2023 According to an AIM ImmunoTech media release, phase 2 is ongoing and topline interim results expected before year end.